跳到正文
Rohan Paul· @rohanpaul_ai · X·· 2026-08-19AI 评分52
AI 导读

Anthropic 让 Claude 自主完成计算蛋白质设计全流程,无需人类专家逐项决策。在 1,320 个设计中,354 个成功结合靶标(命中率 26.8%),并为 15 个靶标中的 14 个找到结合剂;在 6 个可比竞赛靶标中,Claude 在 4 个上命中率更高。

正文 · 原文

Anthropic published one of its most ambitious scientific experiments with Claude yet.

Anthropic showed that Claude can take a biological target and autonomously run the computational protein-design campaign needed to produce binders that actually work in the lab.

A lab may no longer need a dedicated protein-design expert to manually run every computational step. This can move the bottleneck from designing and triaging thousands of candidates toward experimentally testing a much smaller, AI-selected set

- Given a detailed expert-written protocol, it researched each target, chose where to bind, installed and ran open-source protein-design tools, generated candidates, filtered and improved them, then picked the final proteins for lab testing. Humans did not make the individual design decisions.

- The designs actually worked in the lab. Across 1,320 designs with usable measurements, 354 bound their intended targets, a 26.8% hit rate, and Claude found binders for 14 of 15 targets.

- On several targets, its results were competitive with human/open design competitions. Claude had higher hit rates on 4 of 6 comparable competition targets.

- Giving the agent more attention and compute seems to help. Mythos Preview reached a 35.1% hit rate when each target received its own 24-hour campaign, versus 26.7% when many targets shared a 48-hour campaign.

- The AI still cannot reliably know when a whole campaign has failed. Some unsuccessful targets received computational scores similar to successful ones.

引用Anthropic@AnthropicAI
Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per target, sifting through a large number of candidates to identify the few that work. We wanted to test if Claude could successfully design novel protein binders from scratch (also called de novo design). With a protein design prompt written by a human expert, Claude autonomously designed protein binders against 14 out of 15 targets. We then worked with Adaptyv Bio and Twist Bioscience, who independently built and tested the proteins Claude designed.
在 X 查看被引用的帖子

来源:Rohan Paul · x.com